Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders L Carlson

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 18, 2019
EVALUATION OF INSULIN GLARGINE AND EXENATIDE ALONE AND IN COMBINATION: A RANDOMIZED CLINICAL TRIAL WITH CONTINUOUS GLUCOSE MONITORING AND AMBULATORY GLUCOSE PROFILE ANALYSISAnders L Carlson, Deborah M Mullen, Roger Mazze, et al.
Diabetes Technology & Therapeutics|June 7, 2019
Utilizing the Ambulatory Glucose Profile to Standardize and Implement Continuous Glucose Monitoring in Clinical PracticeMary L Johnson, Thomas W Martens, Amy B Criego, et al.
Journal of Diabetes Science and Technology|January 15, 2019
The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1cRoy W Beck, Richard M Bergenstal, Peiyao Cheng, et al.
Diabetes, Obesity & Metabolism|September 28, 2018
Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trialJohn B Buse, Anders L Carlson, Mitsuhisa Komatsu, et al.
BMJ Open Diabetes Research & Care|January 21, 2022
Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysisAnders L Carlson, Timothy Dilon Daniel, Andrea DeSantis, et al.
Postgraduate Medicine|December 14, 2020
Making sense of glucose metrics in diabetes: linkage between postprandial glucose (PPG), time in range (TIR) & hemoglobin A1c (A1C)Thomas W Martens, Richard M Bergenstal, Teresa Pearson, et al.
Diabetes Technology & Therapeutics|June 28, 2022
Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes PopulationsGregory P Forlenza, Anders L Carlson, Rodolfo J Galindo, et al.
Diabetes, Obesity & Metabolism|October 9, 2024
Glycaemic outcomes in adults with type 2 diabetes over 34 weeks with the Omnipod® 5 Automated Insulin Delivery SystemGeorgia M Davis, Anne L Peters, Bruce W Bode, et al.
Diabetes Technology & Therapeutics|April 12, 2021
What's Wrong with This Picture? A Critical Review of Current Centers for Medicare & Medicaid Services Coverage Criteria for Continuous Glucose MonitoringRodolfo J Galindo, Christopher G Parkin, Grazia Aleppo, et al.
Diabetes Care|February 14, 2023
Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes: From Injections to Hybrid Closed-Loop TherapyGeorgia M Davis, Anne L Peters, Bruce W Bode, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 18, 2019
EVALUATION OF INSULIN GLARGINE AND EXENATIDE ALONE AND IN COMBINATION: A RANDOMIZED CLINICAL TRIAL WITH CONTINUOUS GLUCOSE MONITORING AND AMBULATORY GLUCOSE PROFILE ANALYSISAnders L Carlson, Deborah M Mullen, Roger Mazze, et al.
Diabetes Technology & Therapeutics|June 7, 2019
Utilizing the Ambulatory Glucose Profile to Standardize and Implement Continuous Glucose Monitoring in Clinical PracticeMary L Johnson, Thomas W Martens, Amy B Criego, et al.
Journal of Diabetes Science and Technology|January 15, 2019
The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1cRoy W Beck, Richard M Bergenstal, Peiyao Cheng, et al.
Diabetes, Obesity & Metabolism|September 28, 2018
Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trialJohn B Buse, Anders L Carlson, Mitsuhisa Komatsu, et al.
BMJ Open Diabetes Research & Care|January 21, 2022
Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysisAnders L Carlson, Timothy Dilon Daniel, Andrea DeSantis, et al.
Postgraduate Medicine|December 14, 2020
Making sense of glucose metrics in diabetes: linkage between postprandial glucose (PPG), time in range (TIR) & hemoglobin A1c (A1C)Thomas W Martens, Richard M Bergenstal, Teresa Pearson, et al.
Diabetes Technology & Therapeutics|June 28, 2022
Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes PopulationsGregory P Forlenza, Anders L Carlson, Rodolfo J Galindo, et al.
Diabetes, Obesity & Metabolism|October 9, 2024
Glycaemic outcomes in adults with type 2 diabetes over 34 weeks with the Omnipod® 5 Automated Insulin Delivery SystemGeorgia M Davis, Anne L Peters, Bruce W Bode, et al.
Diabetes Technology & Therapeutics|April 12, 2021
What's Wrong with This Picture? A Critical Review of Current Centers for Medicare & Medicaid Services Coverage Criteria for Continuous Glucose MonitoringRodolfo J Galindo, Christopher G Parkin, Grazia Aleppo, et al.
Diabetes Care|February 14, 2023
Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes: From Injections to Hybrid Closed-Loop TherapyGeorgia M Davis, Anne L Peters, Bruce W Bode, et al.
Pageof 6